Skip to main content
SpringerLink
Log in

Ergebnisse einer 5-Jahres-Studie mit Captopril bei Patienten mit schwerer therapieresistenter Hypertonie

Results of a five-year study of captopril in patients with severe therapy-resistant hypertension

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

The angiotensin converting enzyme (ACE) inhibitor captopril proved to be an effective antihypertensive drug during a 5-year follow-up study of patients with severe hypertension who had been resistant to a triple-drug regimen. Of the 42 patients, 41 had to be treated additionally with diuretics. Because of hypokalemia, potassium supplements were necessary in 26 patients, despite the use of “potassium-saving” diuretics in 12 patients.

Blood pressure was controlled sufficiently in 3/4 of the patients during the 5 years.

Patients with a large elevation in plasma renin activity showed the best response to the treatment. Six patients died during the 5 years. Therapy had to be stopped in 11 patients because of complications. The following complications and adverse effects were observed: cerebral ischemia (n=10), vertigo and orthostasis (10), exanthema (9), hypogeusia (7), circulatory failure (7), myocardial infarction (6), and scintigraphically demonstrable decrease of renal perfusion (5).

One patient with bilateral renal artery stenosis suffered from acute renal failure, which was reversible after withdrawal of captopril. Significant changes of red and white blood cell counts, transaminases, lipids, urine protein excretion, and heart rate were not observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ACE:

Angiotensin converting enzyme

PRA:

Plasmareninaktivität

RR:

Blutdruck

Literatur

  1. Andren L, Karlberg BE, Svensson A, Öhmen P, Nilsson OR, Hansson L (1985) Long-term effects of Captopril and Atenolol in essential hypertension. Acta Med Scand 217:155–160

    Google Scholar 

  2. Atkinson AB, Robertson JIS (1979) Captopril in the treatment of clinical hypertension and cardiac failure. Lancet II:836–839

    Google Scholar 

  3. Atkinson AB, Lever AF, Brown JJ, Robertson JIS (1980) Combined treatment of severe intractable hypertension with Captopril and diuretic. Lancet II:105–108

    Google Scholar 

  4. Baker KM, Johns DW, Ayers CR, Carey RM (1980) Ischemic cardiovascular complications concurrent with administration of Captopril. A clinical note. Hypertension 2:73–74

    Google Scholar 

  5. Breckenridge A, Dollery CT, Parry EHD (1970) Prognosis of treated hypertension. Quart J Med 39:411–429

    Google Scholar 

  6. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini G, Vukovich R, McKinstry DN, Gavras J (1979) Oral angiotensin-converting-enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 90:19–23

    Google Scholar 

  7. Case DB, Atlas SA, Sullivan PA, Laragh JH (1981) Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting-enzyme inhibitor Captopril. Circulation 64:765–771

    Google Scholar 

  8. Case DB, Atlas SA, Marion RM, Laragh JH (1982) Long-term efficacy of Captopril in renovascular and essential hypertension. Am J Cardiol 49:1440–1446

    Google Scholar 

  9. Cody RJ, Bravo EL, Fouad FM, Tarazi RC (1981) Cardiovascular reflexes during long-term converting enzyme inhibition and sodium depletion. Am J Med 71:422–426

    Google Scholar 

  10. Cooper RC (1983) Captopril-associated neutropenia. Arch Intern Med 143:659–660

    Google Scholar 

  11. Edwards CRW, Padfield PL (1985) Angiotensin-converting-enzyme inhibitors. Past, present and bright future. Lancet I:30–35

    Google Scholar 

  12. Ferguson RK, Vlasses PH, Koplin JR, Shirinian A, Barke JF, Alexander JC (1980) Captopril in severe treatment-resistant hypertension. Am Heart J 99:579–585

    Google Scholar 

  13. Glück Z, Beretta-Piccoli C, Reubi FC (1984) Long-term effects of Captopril on renal function in hypertensive patients. Euro J Clin Pharmacol 26:315–323

    Google Scholar 

  14. Goodfield MJ, Millard LG (1985) Severe cutaneous reactions to Captopril. Brit Med J 290:1111

    Google Scholar 

  15. Green KG (1979) Optimised blood-pressure. Lancet II:33

    Google Scholar 

  16. Gröne J-H, Kirchertz EJ, Rieger J (1981) Mögliche Komplikationen und Probleme der Captopriltherapie bei Hypertonikern mit ausgeprägten Gefäßschäden. Therapiewoche 31:5280–5287

    Google Scholar 

  17. Gröne H-J, Helmchen U, Kirchertz EJ, Rieger J, Scheler F (1982) Captopril bei Nierenarterienstenosen. Verh Dtsch Ges Inn Med 88:769–771

    Google Scholar 

  18. Guazzi Md, DeCesare N, Galli C, Salvioni A, Tramontana C, Tambosini G, Bartorelli A (1984) Calcium-channel blockade with nifedipine and angiotensin-converting-enzyme inhibition with Captopril in the therapy of patients with severe primary hypertension. Hypertension 70:279–284

    Google Scholar 

  19. Guillevin L, Lardoux M-D, Corrol P (1981) Effects of Captopril on blood pressure, electrolytes and certain hormones in hypertension. Clin Pharm Therap 29:699–704

    Google Scholar 

  20. Havetke J, Vetter H, Studer A, Greminger P, Lüscher T, Wollnik S, Sigenthaler W, Vetter W (1982) Acute and chronic effects of the angiotensin-converting-enzyme inhibitor Captopril in severe hypertension. Am J Cardiol 49:1467–1474

    Google Scholar 

  21. Helmchen U, Gröne H-J, Kirchertz EJ, Bader H, Bohle RM, Kneissler U, Khosla MC (1982) Contrasting renal effects of different antihypertensive agents in hypertensive rats with bilaterally constricted renal arteries. Kid Int 22 (Suppl 12) S 198-S205

    Google Scholar 

  22. Hodsman GP, Isles CG, Murray GD, Usterwood TP, Webb DJ, Robertson JIS (1983) Factors related to first dose hypotensive effect of Captopril: prediction and treatment. Brit Med J 286:832–887

    Google Scholar 

  23. Hodsman GP, Robertson JIS (1983) Captopril: five years on. Brit Med J 287:851–852

    Google Scholar 

  24. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ (1983) Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Engl J Med 308:373–376

    Google Scholar 

  25. Karlberg BE, Asplund J, Nilsson OR, Weltre S, Öhman KP (1981) Captopril an orally active converting enzyme inhibitor in the treatment of primary hypertension. Acta Med Scand 209:245–252

    Google Scholar 

  26. Karlberg BE, Asplund J, Weltre S, Öhman KP, Nilsson OR (1982) Long-term experiance of Captopril in the treatment of primary (essential) hypertension. Br J Clin Pharmacol 14:133S-137S

    Google Scholar 

  27. Kirchertz EJ, Scheler F (1981) Klinisch-praktische Aspekte der Therapie mit Captopril. Therapiewoche 31:5252–5323

    Google Scholar 

  28. Laher MS, Donohoe JFD, O'Regan P, Counihan TB (1985) Captopril for refractory hypertension in patients with impaired renal function. J Royal Soc Med 78:367–372

    Google Scholar 

  29. Laragh JH, Case DB, Atlas SA, Sealey JE (1980) Cantopril compared with other antirenin system agents, in: Hypertensive Patients: Its Triphasic Effects on Blood Pressure and Its Use to Identify and Treatment the Renin Factor. Hypertension 2:586–593

    Google Scholar 

  30. Lew EA (1973) High blood pressure, other risk factors and longevity: The insurance viewpoint. Am J Med 55:281–294

    Google Scholar 

  31. Lijnen P, Staessen J, Fagand R, Amery A (1982) Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 49:1561–1563

    Google Scholar 

  32. MacGregor GA, Markandu ND, Banks RA et al. (1982) Captopril in essential hypertension: Contrasting effects of adding hydrochlorothiazid or propanolol. Br Med J Clin Res 284:693–696

    Google Scholar 

  33. Öhman P, Aurell M, Asplund J, Conradsson T, Delin K, Forslund T, Fyhrquist F, Frithz G, Herlitz H, Karlberg B, Nilsson O, Rhyden L, Welte S (1984) A long-term followup of patients with essential hypertension treated with captopril. Acta Med Scand 216:53–56

    Google Scholar 

  34. Overlack A, Stumpe KO, Heck I, Krück F (1980) Neues Prinzip in der Langzeitbehandlung der essentiellen Hypertension. Dtsch Med Wochenschr 105:505–509

    Google Scholar 

  35. Patrassi GM, Fallo F, Martinelli S, Mankro F, Boeri G, Givolami A (1984) The contact plase of blood coagulation and renin activation in essential hypertension before and after Captopril. Euro Heart J 5:561–567

    Google Scholar 

  36. Perry M, Wessler S (1969) Survival of treated hypertensive patients. JAMA 210:890–895

    Google Scholar 

  37. Rahmat J, Gelfand RL, Gelfand MC, Winchester JF, Schreiner GE, Zimmermann HJ (1985) Captopril-associated cholestatic Jaundice. Ann Intern Med 102:56–58

    Google Scholar 

  38. Raine AEG, Ledingham JGG (1982) Clinical experience with Captopril in the treatment of severe drug-resistant hypertension. Am J Cardio 49:1475–1479

    Google Scholar 

  39. Scheler F, Gröne H-J (1982) Typische Risiken bei der Behandlung der arteriellen Hypertonie. Internist 23:127–132

    Google Scholar 

  40. Scheler F, Valentin R (1984) Kritische Bemerkungen zur Hochdrucktherapie. Internist 25:398–403

    Google Scholar 

  41. Schrader J, Köstering H, Gröne H-J, Kirchertz EJ, Scheler F (1982) Effects of the converting-enzyme-inhibitor Captopril on blood coagulation and fibrinolysis in man. Klin Wochenschr 60:687–690

    Google Scholar 

  42. Seedat YK, Rawat R (1983) Captopril combined with Minoxidil, Betablocker and Furosemid in the treatment of refractory hypertension. Eur J Clin Pharmacol 25:9–11

    Google Scholar 

  43. Sokolow M, Perloff D (1961) The prognosis of essential hypertension treated conservatively. Circulation 23:697–713

    Google Scholar 

  44. Stewart I, Mc DG (1979) Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet I:861–865

    Google Scholar 

  45. Stimpel M, Velter W, Groth H, Greminger P, Vetter H (1985) Captopril before and after Spironolactone therapy in primary aldosteronism. Klin Wochenschr 63:361–363

    Google Scholar 

  46. Stornello M, DiRao G, Iachello M, Pisani K, Scapellato L, Pedrinelli R, Salvetti A (1983) Hemodynamic and humoral interactions between captopril and nifedipine. Hypertension 5 (Suppl II):154–156

    Google Scholar 

  47. Strandgaard S, Olesen J, Skinhög E, Lassen NA (1976) Autoregulation of cerebral blood flow in hypertensive patients. Circulation 53:720–727

    Google Scholar 

  48. Stumpe KO, Kolloch K, Overlack A (1984) Captopril und Enalapril: Therapeutische Effektivität und Sicherheit. Therapiewoche 34:3290–3298

    Google Scholar 

  49. Taguchi J, Freis ED (1974) Partial reduction of blood pressure and prevention of complications in hypertension. N Engl J Med 291:329–331

    Google Scholar 

  50. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1984) Low-dose Captopril for the treatment of mild to moderate hypertension. Arch Intern Med 144:1947–1953

    Google Scholar 

  51. Vidt DG, Bravoe EC, Fouad FM (1982) Captopil. N Engl J Med 306:214–219

    Google Scholar 

  52. Weinberger MH (1983) Influence of an angiotensin-converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 5 (Suppl 13):III-132–III-138

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Nephrologie, Medizinische Universitäts-Klinik, Göttingen

    J. Schrader, G. Schoel & F. Scheler

Authors
  1. J. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Schoel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Scheler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrader, J., Schoel, G. & Scheler, F. Ergebnisse einer 5-Jahres-Studie mit Captopril bei Patienten mit schwerer therapieresistenter Hypertonie. Klin Wochenschr 64, 695–700 (1986). https://doi.org/10.1007/BF01712054

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01712054

Key words

Search

Navigation